KDNY
Income statement / Annual
Last year (2022), Chinook Therapeutics, Inc.'s total revenue was $6.13 M,
a decrease of 88.13% from the previous year.
In 2022, Chinook Therapeutics, Inc.'s net income was -$184.62 M.
See Chinook Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$6.13 M |
$51.63 M |
$827,000.00 |
$17.26 M |
$15.09 M |
$17.24 M |
$50.68 M |
$72.98 M |
Cost of Revenue |
$1.72 M
|
$1.69 M
|
$422,000.00
|
$554,000.00
|
$584,000.00
|
$559,000.00
|
$549,000.00
|
$89,000.00
|
Gross Profit |
$4.41 M
|
$49.94 M
|
$405,000.00
|
$16.70 M
|
$14.50 M
|
$16.68 M
|
$50.13 M
|
$72.89 M
|
Gross Profit Ratio |
0.72
|
0.97
|
0.49
|
0.97
|
0.96
|
0.97
|
0.99
|
1
|
Research and Development Expenses |
$141.21 M
|
$96.99 M
|
$36.05 M
|
$17.01 M
|
$75.84 M
|
$89.38 M
|
$87.72 M
|
$58.65 M
|
General & Administrative Expenses |
$36.29 M
|
$31.90 M
|
$19.07 M
|
$2.96 M
|
$36.04 M
|
$33.75 M
|
$34.28 M
|
$27.81 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$36.29 M
|
$31.90 M
|
$19.07 M
|
$2.96 M
|
$36.04 M
|
$33.75 M
|
$34.28 M
|
$27.81 M
|
Other Expenses |
$1.72 M
|
$1.69 M
|
$422,000.00
|
$299,000.00
|
$3.99 M
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$179.22 M
|
$130.57 M
|
$55.54 M
|
$19.97 M
|
$115.86 M
|
$123.13 M
|
$122.00 M
|
$86.45 M
|
Cost And Expenses |
$179.22 M
|
$130.57 M
|
$55.54 M
|
$19.97 M
|
$116.45 M
|
$123.69 M
|
$122.54 M
|
$86.54 M
|
Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$7.18 M
|
$0.00
|
$15,000.00
|
$33,000.00
|
$0.00
|
$0.00
|
$2.22 M
|
$494,000.00
|
Depreciation & Amortization |
$20.89 M
|
$41.87 M
|
$2.25 M
|
$520,000.00
|
$4.95 M
|
$3.99 M
|
$2.55 M
|
$0.00
|
EBITDA |
-$164.20 M |
-$57.17 M |
-$53.98 M |
-$19.45 M |
-$101.36 M |
-$106.45 M |
-$71.86 M |
-$13.56 M |
EBITDA Ratio |
-26.79
|
-1.11
|
-65.27
|
-1.13
|
-6.72
|
-6.18
|
-1.42
|
-0.19
|
Operating Income Ratio |
-30.2
|
-1.92
|
-67.99
|
-1.16
|
-6.72
|
-6.18
|
-1.42
|
-0.19
|
Total Other Income/Expenses Net |
$4.81 M
|
-$170,000.00
|
-$27.40 M
|
-$64.82 M
|
$5.22 M
|
$3.23 M
|
$2.18 M
|
-$25.74 M
|
Income Before Tax |
-$180.27 M
|
-$99.21 M
|
-$83.63 M
|
-$46.52 M
|
-$96.14 M
|
-$103.23 M
|
-$69.68 M
|
-$39.31 M
|
Income Before Tax Ratio |
-29.42
|
-1.92
|
-101.12
|
-2.7
|
-6.37
|
-5.99
|
-1.37
|
-0.54
|
Income Tax Expense |
$4.34 M
|
$2.09 M
|
-$2.00 M
|
$332,000.00
|
$783,000.00
|
$11.36 M
|
-$21.46 M
|
-$99,000.00
|
Net Income |
-$184.62 M
|
-$101.30 M
|
-$81.62 M
|
-$46.85 M
|
-$95.36 M
|
-$91.86 M
|
-$91.15 M
|
-$39.21 M
|
Net Income Ratio |
-30.13
|
-1.96
|
-98.7
|
-2.71
|
-6.32
|
-5.33
|
-1.8
|
-0.54
|
EPS |
-2.87 |
-2.22 |
-6.2 |
-1.11 |
-0.0012 |
-0.0013 |
-0.0014 |
-0.0009 |
EPS Diluted |
-2.87 |
-2.22 |
-6.2 |
-1.11 |
-0.0012 |
-0.0013 |
-0.0014 |
-0.0009 |
Weighted Average Shares Out |
$64.37 M
|
$45.61 M
|
$13.17 M
|
$42.16 M
|
$78.81 B
|
$72.90 B
|
$65.20 B
|
$44.71 B
|
Weighted Average Shares Out Diluted |
$64.37 M
|
$45.61 M
|
$13.17 M
|
$42.16 M
|
$78.81 B
|
$72.90 B
|
$65.20 B
|
$44.71 B
|
Link |
|
|
|
|
|
|
|
|